Steven Nagelberg, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1619917267
Payments from drug & device makers
Across 1,236 payments — averaging $390.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$435K
- Eli Lilly$39K
- Merck$3K
- Johnson & Johnson$3K
- Medtronic$1K
- Novo Nordisk$250
- plus $548 from 13 others
Across 1 payment — averaging $1469.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 1,142 | $435,495 |
| Eli Lilly | 6 | $38,864 |
| Merck | 5 | $3,128 |
| Johnson & Johnson(2 entities) | 9 | $2,909 |
| Medtronic(2 entities) | 32 | $1,449 |
| Novo Nordisk | 14 | $250 |
| Insulet Corporation | 4 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $89 |
| Dexcom, Inc. | 4 | $88 |
| Tandem Diabetes Care, Inc. | 3 | $42 |
| Boehringer Ingelheim | 2 | $42 |
| Abbott | 2 | $38 |
| Lilly USA, LLC | 2 | $36 |
| Senseonics, Incorporated | 1 | $25 |
| Radius Health, Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| AbbVie | 1 | $20 |
| AstraZeneca | 1 | $13 |
| BETA Bionics, Inc. | 1 | $10 |
How this compares
$482,643 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Philadelphia
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Intekhab AhmedPhiladelphia$926K
- Jane MayrinPhiladelphia$628K
- Michael RickelsPhiladelphia$606K
- Kevin WilliamsPhiladelphia$137K
- Laura YoungPhiladelphia$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.